BRENUS-PHARMA
22.1.2024 18:01:34 CET | Business Wire | Press release
Brenus Pharma announces the financing of nearly 5 million euros for its STC-1010 project as the winner of the "Innovations in Biotherapy and Bioproduction" call for proposals from France 2030. Operated on behalf of the French government by Bpifrance, this support aims to catalyze and maintain excellence in biotherapy research and places Brenus Pharma among the key players of French Biotherapy.
STC-1010: A proteomics-guided cellular immunotherapy to fight cancer relapses.
Brenus Pharma has developed the anti-cancer vaccine STC-1010, targeting metastatic colorectal cancer (mCRC), second leading cause of cancer mortality worldwide. The project's aims are to finalize the development of STC-1010, ensuring its bioproduction and industrialization, and to carry out, in support of the fundraising, the first phase Ia/Ib clinical trial. These crucial steps, which follow the regulatory validation of the pre-clinical package, will provide the first data on the safety and efficacy of the vaccine in humans.
"Brenus Pharma stands out for its innovative platform that generates new cellular and vaccine immunotherapies guided by proteomics. These therapies are based on in vitro reproduction of the proteomic signatures of resistant tumors. This innovation allows us to educate the patients' immune system to recognize and target these resistance mechanisms that usually escape its surveillance. We thank the State via France 2030 for this support, which validates Brenus' technological approach and should accelerate its availability to patients," said Paul BRAVETTI, CEO of Brenus Pharma.
Brenus Pharma, strong territorial anchorage to consolidate the French Advanced Therapy Medicinal Product (ATMP) industry.
This project is part of a national effort to consolidate the French innovative therapy (ATMP) drug industry through the Biotherapy-Bioproduction acceleration strategy coordinated by the French Health Innovation Agency, involving many SMEs with strong regional ties. Brenus aims to contribute not only to scientific and therapeutic innovation in the field of oncology, but also to the influence of French biotechnological excellence.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122731907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
IFF Declares Dividend for Second Quarter 202629.4.2026 22:25:00 CEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2026 to shareholders of record as of June 18, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260429658065/en/
Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn29.4.2026 20:25:00 CEST | Press release
Strong performance reflects sustained upward momentum driven by international expansion and operational efficiencyDigital transformation initiatives in automation and artificial intelligence enhanced productivity, governance, and cost optimization Estithmar Holding Q.P.S.C. announced its financial results for the first quarter of 2026, reporting a net profit of QAR 333 million, marking a significant 97% increase compared to the same period last year. The results underscore the strength of the Company’s operating model and the successful execution of its expansion strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429718889/en/ Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn (Photo: AETOSWire) The company recorded revenues of QAR 1.455 billion, up from QAR 1.309 billion in Q1 2025. Gross profit rose to QAR 561 million compared to QAR 416 million, representing a year-on-year increase of
DC Secretary Announces Annual Determinations Committees Outcome29.4.2026 15:36:00 CEST | Press release
DC Administration Services, Inc. has today announced the composition of five regional Determinations Committees (DCs), effective from April 29, 2026. Global Dealer Voting Members (for all Regions): Non-Dealer Voting Members (for all Regions): Bank of America, N.A. Citadel Americas LLC Barclays Bank plc Elliott Investment Management L.P. BNP Paribas Pacific Investment Management Company LLC Citibank, N.A. Deutsche Bank AG Goldman Sachs International JPMorgan Chase Bank, N.A. Regional Dealer Voting Member for the Americas, EMEA, Asia Ex-Japan, and Japan Determination Committees: CCP Members for the Americas, EMEA, Asia Ex-Japan, and Australia-New Zealand Determinations Committees: Mizuho Securities Co., Ltd. ICE Clear Credit LLC LCH S.A. The process for selecting DC members is specified in the DC rules. The DC rules, along with more information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommitte
Driscoll's Names Wyard Stomp Chief Operating Officer and Expands Shaily Sanghvi's Role to Lead Global Strategy29.4.2026 15:00:00 CEST | Press release
Leadership announcements advance Driscoll's global ambition to scale its proven mission of delighting consumers to every market worldwide Driscoll's, the world's leading berry brand, today announced two leadership appointments to support CEO Soren Bjorn's long-term strategy to scale the company's proven, flavor-first business model globally, bringing the same deliberate approach that made Driscoll's the #2 retail food and beverage brand in the United States to consumers in every market the company serves. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429432633/en/ Wyard Stomp has been appointed Chief Operating Officer (COO), a newly created role, while continuing to lead Driscoll's Europe, Middle East, and Africa (EMEA) business. As COO, Stomp will partner closely with the Executive Leadership Team to turn strategy into action, lead cross-functional initiatives, and ensure the company executes at the pace required to sup
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom